Old drug, new trick: colchicine may stop AFib after heart bypass
NCT ID NCT07611019
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether colchicine, a drug usually used for gout, can prevent atrial fibrillation (a type of irregular heartbeat) after coronary artery bypass surgery. About 400 adults scheduled for elective bypass will receive either colchicine or a placebo starting 3 days before surgery and continuing for a week after. The main goal is to see if colchicine reduces the number of people who develop this heart rhythm problem within 14 days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- colchicine
- What this could lead to
- If it works, this could provide a simple, low-cost way to prevent a common heart-rhythm complication after bypass surgery.
- What could go wrong
- This is an early-to-mid-stage trial with 400 participants, so results may not apply to everyone. Colchicine can cause side effects like stomach upset or, rarely, more serious issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG. * Ability to receive oral study medication before and after surgery. * Provision of written informed consent before randomization. Exclusion Criteria: * History of atrial fibrillation or atrial flutter before surgery. * Severe renal impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m²) or chronic dialysis. * Severe hepatic dysfunction. * Known hypersensitivity or previous severe adverse reaction to colchicine. * Pregnancy or breastfeeding. * Current use of strong CYP3A4 or P-glycoprotein inhibitors that cannot be safely discontinued or substituted. * Any condition judged by the investigators to interfere with study participation or safety assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post-operative atrial fibrillation after coronary artery bypass grafting (CABG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan